Glaxosmi. Pharma Financials Statement

FINANCIALS

Select Period:

Particulars ( Rupees In Crores.)	Sep-2023	Jun-2023	Mar-2023	Dec-2022	Sep-2022
Gross Sales	956.99	761.66	787.45	802.30	916.87
Excise Duty	--	--	--	--	--
Net Sales	956.99	761.66	787.45	802.30	916.87
Other Operating Income	--	--	--	--	--
Other Income	28.21	53.74	38.06	23.42	21.97
Total Income	985.20	815.40	825.51	825.72	938.84
Total Expenditure	667.50	617.78	617.71	584.97	659.94
PBIDT	317.70	197.62	207.80	240.75	278.90
Interest	0.43	0.28	0.65	0.09	0.39
PBDT	317.27	197.34	207.15	240.66	278.51
Depreciation	18.11	16.36	17.18	16.41	16.36
Minority Interest Before NP	--	--	--	--	--
Tax	91.28	53.23	57.30	69.20	73.36
Deferred Tax	(9.63)	(4.50)	(0.76)	(9.51)	(4.63)
Reported Profit After Tax	217.51	132.25	133.43	164.56	193.42
Minority Interest After NP	--	--	--	--	--
Net Profit after Minority Interest	217.51	132.25	133.43	164.56	193.42
Extra-ordinary Items	--	12.21	7.26	(7.86)	--
Adjusted Profit After Extra-ordinary item	217.51	120.04	126.17	172.42	193.42
EPS (Unit Curr.)	12.84	7.04	7.41	9.71	11.42
Book Value (Unit Curr.)	--	--	--	--	--
Dividend (%)	320	--	--	--	--
Equity	169.41	169.41	169.41	169.41	169.41
Public Shareholding (Number)	--	--	--	--	--
Public Shareholding (%)	--	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--	--
PBIDTM(%)	33.20	25.95	26.39	30.01	30.42
PBDTM(%)	33.15	25.91	26.31	30.00	30.38
PATM(%)	22.73	17.36	16.95	20.51	21.10

QuickLinks for Glaxosmithkline Pharmaceuticals Ltd.